JP2004531543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004531543A5 JP2004531543A5 JP2002585457A JP2002585457A JP2004531543A5 JP 2004531543 A5 JP2004531543 A5 JP 2004531543A5 JP 2002585457 A JP2002585457 A JP 2002585457A JP 2002585457 A JP2002585457 A JP 2002585457A JP 2004531543 A5 JP2004531543 A5 JP 2004531543A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- alkyl ester
- alkyl
- carbon atoms
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 claims 46
- 125000004432 carbon atom Chemical group C* 0.000 claims 26
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000002148 esters Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229960002663 thioctic acid Drugs 0.000 claims 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 claims 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 4
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims 4
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims 4
- 229960002733 gamolenic acid Drugs 0.000 claims 4
- 208000019423 liver disease Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims 3
- AGBQKNBQESQNJD-ZETCQYMHSA-N (S)-lipoic acid Chemical compound OC(=O)CCCC[C@H]1CCSS1 AGBQKNBQESQNJD-ZETCQYMHSA-N 0.000 claims 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 3
- -1 carboxylic acid halide Chemical class 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 229960004488 linolenic acid Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims 3
- RGTIBVZDHOMOKC-UHFFFAOYSA-N stearolic acid Chemical compound CCCCCCCCC#CCCCCCCCC(O)=O RGTIBVZDHOMOKC-UHFFFAOYSA-N 0.000 claims 3
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 claims 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims 2
- HQPCSDADVLFHHO-UHFFFAOYSA-N (all-Z)-8,11,14,17-Eicosatetraenoic acid Natural products CCC=CCC=CCC=CCC=CCCCCCCC(O)=O HQPCSDADVLFHHO-UHFFFAOYSA-N 0.000 claims 2
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 claims 2
- AVKOENOBFIYBSA-UHFFFAOYSA-N 4,7,10,13,16-Docosapentaenoic acid Natural products CCCCCC=CCC=CCC=CCC=CCC=CCCC(O)=O AVKOENOBFIYBSA-UHFFFAOYSA-N 0.000 claims 2
- UNSRRHDPHVZAHH-UHFFFAOYSA-N 6beta,11alpha-Dihydroxy-3alpha,5alpha-cyclopregnan-20-on Natural products CCCCCCCCC=CCC=CCC=CCCCC(O)=O UNSRRHDPHVZAHH-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000005019 Chlamydia pneumonia Diseases 0.000 claims 2
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010027439 Metal poisoning Diseases 0.000 claims 2
- 206010028851 Necrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 208000001388 Opportunistic Infections Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- HXQHFNIKBKZGRP-UHFFFAOYSA-N Ranuncelin-saeure-methylester Natural products CCCCCC=CCC=CCCC=CCCCC(O)=O HXQHFNIKBKZGRP-UHFFFAOYSA-N 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 235000021342 arachidonic acid Nutrition 0.000 claims 2
- 229940114079 arachidonic acid Drugs 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000010501 heavy metal poisoning Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000023589 ischemic disease Diseases 0.000 claims 2
- 230000005976 liver dysfunction Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 claims 2
- 150000004291 polyenes Chemical class 0.000 claims 2
- 230000007824 polyneuropathy Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229930002330 retinoic acid Natural products 0.000 claims 2
- 229960003656 ricinoleic acid Drugs 0.000 claims 2
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 229960001727 tretinoin Drugs 0.000 claims 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 2
- 229940045145 uridine Drugs 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- UNSRRHDPHVZAHH-YOILPLPUSA-N (5Z,8Z,11Z)-icosatrienoic acid Chemical compound CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(O)=O UNSRRHDPHVZAHH-YOILPLPUSA-N 0.000 claims 1
- DFJAXEWDHVOILU-UHFFFAOYSA-N (5Z,9E)-5,9-Octadecadienoic acid Natural products CCCCCCCCC=CCCC=CCCCC(O)=O DFJAXEWDHVOILU-UHFFFAOYSA-N 0.000 claims 1
- HXQHFNIKBKZGRP-URPRIDOGSA-N (5Z,9Z,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C\C=C/CC\C=C/CCCC(O)=O HXQHFNIKBKZGRP-URPRIDOGSA-N 0.000 claims 1
- YUFFSWGQGVEMMI-UHFFFAOYSA-N (7Z,10Z,13Z,16Z,19Z)-7,10,13,16,19-docosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCCC(O)=O YUFFSWGQGVEMMI-UHFFFAOYSA-N 0.000 claims 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 1
- DQGMPXYVZZCNDQ-KBPWROHVSA-N (8E,10E,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C=C/C=C/CCCCCCC(O)=O DQGMPXYVZZCNDQ-KBPWROHVSA-N 0.000 claims 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- IJKRDVKGCQRKBI-UHFFFAOYSA-N 11,12-methyleneoctadecanoic acid Chemical compound CCCCCCC1CC1CCCCCCCCCC(O)=O IJKRDVKGCQRKBI-UHFFFAOYSA-N 0.000 claims 1
- ZONJATNKKGGVSU-UHFFFAOYSA-N 14-methylpentadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCC(O)=O ZONJATNKKGGVSU-UHFFFAOYSA-N 0.000 claims 1
- UFOOFOUFKSIFCD-KTKRTIGZSA-N 2-hydroxynervonic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCC(O)C(O)=O UFOOFOUFKSIFCD-KTKRTIGZSA-N 0.000 claims 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 claims 1
- AVKOENOBFIYBSA-GUTOPQIJSA-N 4,7,10,13,16-Docosapentaenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O AVKOENOBFIYBSA-GUTOPQIJSA-N 0.000 claims 1
- MUZYOAHCGSIXJH-UHFFFAOYSA-N 8-(2-hexylcyclopropyl)octanoic acid Chemical compound CCCCCCC1CC1CCCCCCCC(O)=O MUZYOAHCGSIXJH-UHFFFAOYSA-N 0.000 claims 1
- DQGMPXYVZZCNDQ-UVZPLDOLSA-N Calendinsaeure Natural products CCCCCC=C/C=C/C=C/CCCCCCC(=O)O DQGMPXYVZZCNDQ-UVZPLDOLSA-N 0.000 claims 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims 1
- 206010038997 Retroviral infections Diseases 0.000 claims 1
- 208000005074 Retroviridae Infections Diseases 0.000 claims 1
- DFJAXEWDHVOILU-KWUOUXIESA-N Taxoleic acid Chemical compound CCCCCCCC\C=C/CC\C=C/CCCC(O)=O DFJAXEWDHVOILU-KWUOUXIESA-N 0.000 claims 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- HQPCSDADVLFHHO-LTKCOYKYSA-N all-cis-8,11,14,17-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HQPCSDADVLFHHO-LTKCOYKYSA-N 0.000 claims 1
- TWSWSIQAPQLDBP-DOFZRALJSA-N all-cis-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O TWSWSIQAPQLDBP-DOFZRALJSA-N 0.000 claims 1
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000000798 anti-retroviral effect Effects 0.000 claims 1
- 150000001731 carboxylic acid azides Chemical class 0.000 claims 1
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 claims 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims 1
- XIVFQYWMMJWUCD-UHFFFAOYSA-N dihydrophaseic acid Natural products C1C(O)CC2(C)OCC1(C)C2(O)C=CC(C)=CC(O)=O XIVFQYWMMJWUCD-UHFFFAOYSA-N 0.000 claims 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- MGLDCXPLYOWQRP-UHFFFAOYSA-N eicosa-5,8,11,14-tetraynoic acid Chemical compound CCCCCC#CCC#CCC#CCC#CCCCC(O)=O MGLDCXPLYOWQRP-UHFFFAOYSA-N 0.000 claims 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 1
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 claims 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000010374 vitamin B1 Nutrition 0.000 claims 1
- 239000011691 vitamin B1 Substances 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 235000019164 vitamin B2 Nutrition 0.000 claims 1
- 239000011716 vitamin B2 Substances 0.000 claims 1
- 235000019158 vitamin B6 Nutrition 0.000 claims 1
- 239000011726 vitamin B6 Substances 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01110608 | 2001-04-30 | ||
| EP01110608.5 | 2001-04-30 | ||
| US28809001P | 2001-05-03 | 2001-05-03 | |
| US60/288,090 | 2001-05-03 | ||
| EP01124879.6 | 2001-10-18 | ||
| EP01124879 | 2001-10-18 | ||
| US33042901P | 2001-10-22 | 2001-10-22 | |
| US60/330,429 | 2001-10-22 | ||
| PCT/EP2002/004725 WO2002088159A1 (en) | 2001-04-30 | 2002-04-29 | Pharmaceutically active uridine esters |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004531543A JP2004531543A (ja) | 2004-10-14 |
| JP2004531543A5 true JP2004531543A5 (https=) | 2005-09-02 |
| JP4880190B2 JP4880190B2 (ja) | 2012-02-22 |
Family
ID=32598659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002585457A Expired - Fee Related JP4880190B2 (ja) | 2001-04-30 | 2002-04-29 | 医薬として活性なウリジンエステル |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US7560442B2 (https=) |
| JP (1) | JP4880190B2 (https=) |
| EA (1) | EA200301204A1 (https=) |
| EE (1) | EE201100023A (https=) |
| RS (2) | RS20100077A (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| US20050158258A1 (en) * | 2004-01-21 | 2005-07-21 | Mary Kay Inc. | Methods and compositions for the treatment of skin changes associated with aging and environmental damage |
| US8084500B2 (en) * | 2005-01-14 | 2011-12-27 | Nutrition Therapeutics, Inc. | Method of using catalpic acid to treat dyslipidemia |
| US7687544B2 (en) * | 2005-01-14 | 2010-03-30 | Nutrition Therapeutics, Inc. | Method of using catalpic acid to treat type 2 diabetes and associated disorders |
| US8420122B2 (en) * | 2006-04-28 | 2013-04-16 | Merck Sharp & Dohme Corp. | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
| US20080193518A1 (en) * | 2006-04-28 | 2008-08-14 | Schering Corporation | Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same |
| US8329663B2 (en) * | 2008-01-31 | 2012-12-11 | Paul Griffin | Compositions and methods for the treatment of chronic infections |
| WO2009097596A1 (en) * | 2008-01-31 | 2009-08-06 | Paul Griffin | Compositions and methods for the treatment of chronic infections |
| CA2724023C (en) * | 2008-05-13 | 2014-02-18 | Genmedica Therapeutics Sl | Salicylate conjugates useful for treating metabolic disorders |
| US8950583B2 (en) | 2008-12-06 | 2015-02-10 | Ermes Medical Company Limited | Method to remove heavy metals from a mammal |
| US20100239552A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Combination Therapies for Treating Metabolic Disorders |
| JP2012520342A (ja) * | 2009-03-16 | 2012-09-06 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ | 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート |
| CA2775397A1 (en) * | 2009-09-28 | 2011-03-31 | University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use |
| US8575218B2 (en) * | 2009-09-28 | 2013-11-05 | The University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from tissues and formulations therefor |
| US8426368B2 (en) * | 2010-03-25 | 2013-04-23 | The University Of Kentucky Research Foundation | Method of ameliorating oxidative stress and supplementing the diet |
| JP2012041283A (ja) * | 2010-08-17 | 2012-03-01 | Porien Project Kk | 血管新生抑制剤 |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
| CN105612155A (zh) * | 2012-05-10 | 2016-05-25 | 塞利克斯比奥私人有限公司 | 治疗局部疼痛的组合物和方法 |
| JP6463750B2 (ja) * | 2013-10-23 | 2019-02-06 | ケムジーンズ コーポレーション | 固体表面上に生体分子をより強力に固定化するためのジチオラン官能化ヌクレオシドアミダイトおよび担体 |
| EP3002010A1 (en) * | 2014-09-30 | 2016-04-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Food intake, body weight and glucose metabolism regulation by modulation of P2Y6 receptor signaling |
| WO2016008603A1 (en) * | 2014-07-16 | 2016-01-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Food intake, body weight and glucose metabolism regulation by modulation of p2y6 receptor signaling |
| JP6949002B6 (ja) | 2015-08-05 | 2021-11-17 | メトロ インターナショナル バイオテック，エルエルシー | ニコチンアミドモノヌクレオチド誘導体及びそれらの使用 |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| WO2017155386A1 (en) * | 2016-03-08 | 2017-09-14 | N.V. Nutricia | Method for treating brain atrophy |
| US11180521B2 (en) | 2018-01-30 | 2021-11-23 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| US10618927B1 (en) * | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| WO2022251491A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8319073D0 (en) * | 1983-07-14 | 1983-08-17 | Efamol Ltd | Fatty acid compositions |
| CA1321994C (en) * | 1987-10-28 | 1993-09-07 | Reid Von Borstel | Acylated uridine and cytidine and uses thereof |
| US5736531A (en) | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
| US6090839A (en) * | 1996-12-23 | 2000-07-18 | Merck & Co., Inc. | Antidiabetic agents |
-
2002
- 2002-04-29 JP JP2002585457A patent/JP4880190B2/ja not_active Expired - Fee Related
- 2002-04-29 EE EEP201100023A patent/EE201100023A/xx unknown
- 2002-04-29 RS RSP-2010/0077A patent/RS20100077A/sr unknown
- 2002-04-29 RS YUP-765/03A patent/RS51031B/sr unknown
- 2002-04-29 US US10/476,287 patent/US7560442B2/en not_active Expired - Fee Related
- 2002-04-29 EA EA200301204A patent/EA200301204A1/ru unknown
-
2004
- 2004-09-29 US US10/951,724 patent/US7915234B2/en not_active Expired - Fee Related
- 2004-09-29 US US10/951,764 patent/US7396826B2/en not_active Expired - Fee Related
- 2004-09-29 US US10/951,776 patent/US7417034B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004531543A5 (https=) | ||
| KR100660754B1 (ko) | 의약적으로 활성인 우리딘 에스테르 | |
| JP2021165280A (ja) | Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 | |
| JP2021063088A5 (https=) | ||
| JP2004526745A5 (https=) | ||
| EP2672973B1 (en) | Administration regime for nitrocatechols | |
| JP2008543854A5 (https=) | ||
| US20050043269A1 (en) | Pharmaceutically active uridine esters | |
| JP2017531038A5 (https=) | ||
| JP2015500833A5 (https=) | ||
| JP2005530736A5 (https=) | ||
| JP2017526623A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| WO2021222807A1 (en) | Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals | |
| WO2017106710A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| CA2873096A1 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
| JP2026027247A (ja) | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| US11192914B2 (en) | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| US20220193106A1 (en) | Nucleobase analogue derivatives and their applications | |
| JP2025118775A5 (https=) | ||
| JP2023517919A5 (https=) | ||
| JP2010502568A5 (https=) | ||
| JP2009517391A5 (ja) | 胃腸障害の処置のための医薬組成物 | |
| CN108610384B (zh) | 基于肠道mct1载体蛋白设计的前药及其制备方法 | |
| JP2010528088A5 (https=) |